Readoutin 135d
Amgen — Maridebart Cafraglutide
Phase 3 primary completion: Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight.
- Date
- Apr 2027
- Type
- Readout
- Indication
- Obesity
Readoutin 135d
Phase 3 primary completion: Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight.
The weekly brief is free. Pro adds reminders 7 days and 1 day before.